BR112019001082A2 - gel intestinal de levodopa e carbidopa e métodos de uso - Google Patents

gel intestinal de levodopa e carbidopa e métodos de uso

Info

Publication number
BR112019001082A2
BR112019001082A2 BR112019001082-3A BR112019001082A BR112019001082A2 BR 112019001082 A2 BR112019001082 A2 BR 112019001082A2 BR 112019001082 A BR112019001082 A BR 112019001082A BR 112019001082 A2 BR112019001082 A2 BR 112019001082A2
Authority
BR
Brazil
Prior art keywords
methods
levodopa
intestinal gel
carbidopa
carbidopa intestinal
Prior art date
Application number
BR112019001082-3A
Other languages
English (en)
Inventor
Deac Alexandru
Huang Ye
M. Lipari John
Ruggles Alexander
Yu Tun Thin
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of BR112019001082A2 publication Critical patent/BR112019001082A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente revelação fornece (a) uma composição farmacêutica que compreende um agente ativo de levodopa e um agente ativo de carbidopa e (b) métodos para tratamento de mal de parkinson, e afecções associadas, que compreendem administrar a composição farmacêutica a um indivíduo com mal de parkinson.
BR112019001082-3A 2016-07-20 2017-07-20 gel intestinal de levodopa e carbidopa e métodos de uso BR112019001082A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364770P 2016-07-20 2016-07-20
US62/364,770 2016-07-20
PCT/US2017/043103 WO2018017850A1 (en) 2016-07-20 2017-07-20 Levodopa and carbidopa intestinal gel and methods of use

Publications (1)

Publication Number Publication Date
BR112019001082A2 true BR112019001082A2 (pt) 2019-04-30

Family

ID=59506369

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001082-3A BR112019001082A2 (pt) 2016-07-20 2017-07-20 gel intestinal de levodopa e carbidopa e métodos de uso

Country Status (9)

Country Link
US (3) US20180021280A1 (pt)
EP (1) EP3487479A1 (pt)
JP (2) JP2019523249A (pt)
CN (1) CN109715139A (pt)
AU (2) AU2017299710A1 (pt)
BR (1) BR112019001082A2 (pt)
CA (1) CA3031254A1 (pt)
MX (2) MX2019000849A (pt)
WO (1) WO2018017850A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
WO2019166322A1 (en) 2018-03-02 2019-09-06 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
CN1901880A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增加二甲双胍吸收的组合物和剂型
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
DE102006034346B4 (de) * 2006-07-25 2008-11-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum periodischen Messen der Fließgrenze von Dispersionen sowie deren Verwendung
US20150182688A1 (en) * 2013-12-31 2015-07-02 Abbvie Inc. Devices and methods for delivering a beneficial agent to a user
SE538425C2 (en) * 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
WO2016036308A1 (en) * 2014-09-04 2016-03-10 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Also Published As

Publication number Publication date
CA3031254A1 (en) 2018-01-25
WO2018017850A1 (en) 2018-01-25
JP2022166217A (ja) 2022-11-01
CN109715139A (zh) 2019-05-03
MX2019000849A (es) 2019-09-13
EP3487479A1 (en) 2019-05-29
AU2017299710A1 (en) 2019-01-31
US20230129413A1 (en) 2023-04-27
JP2019523249A (ja) 2019-08-22
AU2023203340A1 (en) 2023-06-22
MX2022014577A (es) 2023-01-11
US20180021280A1 (en) 2018-01-25
US20210059968A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
NI202100009A (es) Métodos para reducir la necesidad de revascu
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
CU20200012A7 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
EP4295909A3 (en) Carbidopa and l-dopa prodrugs and methods of use
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112019024566A2 (pt) inibidores de pirazol magl
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
CO2023009085A2 (es) Pauta posológica de levodopa
AR106313A1 (es) Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
BR112018070547A2 (pt) agonistas de rara para o tratamento de aml e mds
UY38473A (es) Formulaciones farmacéuticas para una administración subcutánea

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]